Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SSTR4 | P31391 | 4/20 | 0.59 |
| ▸ | SSTR1 | P30872 | 3/20 | 0.59 |
| ▸ | STS | P08842 | 2/20 | 0.43 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.42 |
| ▸ | NR1D1 | P20393 | 2/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.40 |
| ▸ | VEGFA | P15692 | 1/20 | 0.40 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | IL1B | P01584 | 1/20 | 0.39 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30601837 | 0.91 | SSTR4 (0.48) | SSTR4SSTR1USP30MEN1KMT2A | |
| SCHEMBL30601815 | 0.90 | SSTR4 (0.54) | SSTR4SSTR1STSUSP30SMN1; SMN2 | |
| SCHEMBL30601854 | 0.87 | SSTR4 (0.59) | SSTR4SSTR1USP30TP53 | |
| SCHEMBL30601836 | 0.85 | SSTR4 (0.59) | SSTR4SSTR1STSUSP30MEN1 | |
| SCHEMBL26125685 | 0.85 | SSTR4 (0.61) | SSTR4SSTR1MEN1KMT2A | |
| SCHEMBL30601828 | 0.83 | USP30 (0.45) | SSTR4SSTR1STSUSP30MAPK8 | |
| SCHEMBL30601814 | 0.83 | SSTR1 (0.56) | SSTR4SSTR1USP30MEN1KMT2A | |
| SCHEMBL30601832 | 0.82 | ROCK2 (0.40) | SSTR4SSTR1STSUSP30TP53 | |
| SCHEMBL26128183 | 0.82 | SSTR4 (0.78) | SSTR4SSTR1 | |
| SCHEMBL30601833 | 0.81 | GPR119 (0.42) | SSTR4SSTR1USP30 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250188037-A1 | N-(PYRROLIDIN-3-YL OR PIPERIDIN-4-YL)ACETAMIDE DERIVATIVES | TAKEDA PHARMACEUTICALS CO (JP) | 2025-06-12 | — | — | US | disclosed |
| EP-4499224-A1 | N-(PYRROLIDIN-3-YL OR PIPERIDIN-4-YL)ACETAMIDE DERIVATIVES | Takeda Pharmaceutical Company Limited (JP) | 2025-02-05 | — | — | EP | disclosed |
| WO-2023187677-A1 | N-(PYRROLIDIN-3-YL OR PIPERIDIN-4-YL)ACETAMIDE DERIVATIVES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-10-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250188037-A1 | N-(PYRROLIDIN-3-YL OR PIPERIDIN-4-YL)ACETAMIDE DERIVATIVES | SSTR4, SSTR3, SSTR1 | SSTR4 1/4885SSTR1 3/4885STS 544/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.